id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S9250 R32090 |
Trivedi (Phenytoin) (Controls exposed to Lamotrigine, sick), 2018 | Spontaneous fetal loss (both spontaneous abortion before 20 weeks of gestation and stillbirths occurring after 20 weeks of gestation) | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.92 [0.28;3.10] C excluded (control group) |
10/129 4/48 | 14 | 129 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9251 R32091 |
Trivedi (Phenytoin) (Controls unexposed, sick), 2018 | Spontaneous fetal loss (both spontaneous abortion before 20 weeks of gestation and stillbirths occurring after 20 weeks of gestation) | 1st trimester | prospective cohort | unexposed, sick | Adjustment: Yes | 5.82 [1.43;23.73] | 10/129 5/178 | 15 | 129 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9252 R32092 |
Vajda (Phenytoin) (Controls exposed to Lamotrigine, sick), 2018 | Intrauterine foetal death | throughout pregnancy | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.64 [0.08;5.00] C excluded (control group) |
1/42 14/382 | 15 | 42 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9253 R32093 |
Vajda (Phenytoin) (Controls unexposed, sick), 2018 | Intrauterine foetal death | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 4.05 [0.26;63.39] | 1/42 1/170 | 2 | 42 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9213 R31963 |
Miškov (Phenytoin) (Controls exposed to Lamotrigine, sick), 2016 | Fetal loss | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
7.22 [0.13;411.26] C excluded (control group) |
0/1 4/37 | 4 | 1 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9214 R31967 |
Miškov (Phenytoin) (Controls unexposed, disease free), 2016 | Fetal loss | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free excluded | Adjustment: No |
255.00 [2.09;31113.60] C excluded (control group) |
0/1 0/128 | 0 | 1 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9215 R31971 |
Miškov (Phenytoin) (Controls unexposed, sick), 2016 | Fetal loss | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 7.00 [0.05;953.26] C | 0/1 0/4 | 0 | 1 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9186 R31765 |
Arkilo (Phenytoin), 2015 | Unsuccessful pregnancies (miscarriages/stillbirths) | during pregnancy (anytime or not specified) | retrospective cohort | exposed to other treatment, sick | Adjustment: No | 0.96 [0.04;23.49] C | 0/5 2/24 | 2 | 5 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9212 R31960 |
Meador (Phenytoin), 2006 | Fetal death (early and late intrauterine deaths) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: No | 9.11 [0.43;193.31] C | 2/56 0/98 | 2 | 56 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 5 studies | 4.81 [1.66;13.92] | 21 | 233 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Phenytoin) (Controls unexposed, sick; 2: Phenytoin) (Controls unexposed, sick; 3: Phenytoin) (Controls unexposed, sick; 4: Phenytoin; 5: Phenytoin;
Asymetry test p-value = 0.6486 (by Egger's regression)
slope=1.9488 (0.8210); intercept=-0.3417 (0.6772); t=0.5046; p=0.6486
excluded 9213, 9214, 9250, 9252